Skip to main content

Advertisement

SpringerLink
Log in

Myeloma: Update on supportive care strategies

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Despite substantial innovations in the treatment of multiple myeloma (MM), it remains an incurable disease. In addition, it is debatable whether the progress in survival is attributable simply to the therapy used to destroy the tumor clone or if it is also because of therapy designed to ameliorate disease complications. Supportive therapy has evolved greatly alongside general supportive measures used in hematologic malignancies (such as new antibiotics, antifungal agents, and growth factors) in addition to better indications in complementary treatments such as radiotherapy, dialysis, and surgery. However, in MM, several specific adjuvant therapies have also been introduced (eg, bisphosphonates and erythroid-stimulating factors), which have conferred a key role to supportive therapy in the general treatment of patients with MM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. San Miguel JF, Blade J, García-Sanz R: Treatment of multiple myeloma. Haematologica 1999, 84:36–58.

    Google Scholar 

  2. San Miguel JF: Supportive therapy for complications in multiple myeloma. In Education Sessions of the Second Meeting of the European Haematology Association, 1996. Blackwell Science Ltd; 1996:12-16.

  3. San Miguel JF, García-Sanz R: Recombinant human erythropoietin in the anaemia of multiple myeloma and non-Hodgkin’s lymphoma. Med Oncol 1998, 15(Suppl 1):S29-S34.

    Google Scholar 

  4. Silvestris F, Cafforio P, Tucci M, Dammacco F: Negative regulation of erythroblast maturation by Fas-L+/ TRAIL+ highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood 2002, 99:1305–1313.

    Article  PubMed  CAS  Google Scholar 

  5. Garton JP, Gertz MA, Witzig TE, et al.: Epoietin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled double blind trial. Arch Intern Med 1995, 155:2069–2074.

    Article  PubMed  CAS  Google Scholar 

  6. Cazzola M, Messinger D, Battistel V, et al.: Recombinant human erythropoietin in the anemia associated with multiple myeloma and non-Hodgkin’s lymphoma: dose finding and identification of predictors of response. Blood 1995, 86:4446–4453.

    PubMed  CAS  Google Scholar 

  7. Osterborg A, Boogaerts MA, Cimino R, et al.: Recombinant human erythropoietin in transfusiondependent patients with multiple myeloma and non-Hodgkin’s lymphoma: a randomized multicenter study. The European Study Group of Erythropoietin (Epoietin Beta) Treatment in Multiple Myeloma and Non-Hodgkin’s Lymphoma. Blood 1996, 87:2675–2682.

    PubMed  CAS  Google Scholar 

  8. Littlewood TJ, Bajetta E, Nortier JW, et al.: Effects of epoietin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001, 19:2865–2874.

    PubMed  CAS  Google Scholar 

  9. Dammacco F, Castoldi G, Rodjer S: Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001, 113:172–179.

    Article  PubMed  CAS  Google Scholar 

  10. Osterborg A, Brandberg Y, Molostova V, et al.: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematological malignancies. J Clin Oncol 2002, 20:2486–2494. Randomized studies that have shown the advantage (eg, hemoglobin increase and reduction of transfusions) of treating MM with recombinant human EPO versus no treatment.

    Article  PubMed  CAS  Google Scholar 

  11. Ludwig H, Rai K, Blade J, et al.: Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. Hematol J 2002, 3:121–130.

    Article  PubMed  CAS  Google Scholar 

  12. Rizzo JD, Lichtin AE, Woolf SH, et al.: Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002, 100:2303–2320. Recommendations from two expert panels to define the use of rHuEPO in anemic patients with cancer, including patients with MM.

    Article  PubMed  CAS  Google Scholar 

  13. Egrie JC, Browne JK: Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001, 84(Suppl 1):3–10.

    Article  PubMed  CAS  Google Scholar 

  14. Hedenus M, Hansen S, Taylor K, et al.: Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 2002, 119:79–86.

    Article  PubMed  CAS  Google Scholar 

  15. Cazzola M, Mercuriali F, Brugnara C: Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997, 89:4248–4267.

    PubMed  CAS  Google Scholar 

  16. Mittelman M, Neumann D, Peled A, et al.: Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci U S A 2001, 98:5181–5186.

    Article  PubMed  CAS  Google Scholar 

  17. http://home.intekom.com/pharm/janssen/eprex.html. Accessed February 11, 2003.

  18. Hargreaves RM, Lea JR, Griffiths H, et al.: Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol 1995, 48:260–266.

    Article  PubMed  CAS  Google Scholar 

  19. Fassas AB, Bolanos-Meade J, Buddharaju LN, et al.: Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma. Br J Haematol 2001, 112:1032–1033.

    Article  Google Scholar 

  20. Lortholary O, Ascioglu S, Moreau P, et al.: Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the Intergroupe Francais du Myeloma. Clin Infect Dis 2000, 30:41–46.

    Article  PubMed  CAS  Google Scholar 

  21. Vallejo C, Caballero MD, García-Sanz R, et al.: Sequential intravenous-oral ciprofloxacin plus amoxycillin/ clavulanic acid shortens hospital stay in infected non-severe neutropenic patients. Hematol Cell Ther 1997, 39:223–227.

    Article  PubMed  CAS  Google Scholar 

  22. Oken MM, Pomeroy C, Weisdorf D, Bennett JM: Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 1996, 100:624–628.

    Article  PubMed  CAS  Google Scholar 

  23. Ljungman P: Immunization of transplant recipients. Bone Marrow Transplant 1999, 23:635–636.

    Article  PubMed  CAS  Google Scholar 

  24. Chapel HM, Lee M, Hargreaves R, et al.: Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 1994, 343:1059–1063.

    Article  PubMed  CAS  Google Scholar 

  25. Alexanian R, Barlogie B, Dixon D: Renal failure in multiple myeloma: pathogenesis and prognostic implications. Arch Intern Med 1990, 150:1693–1695.

    Article  PubMed  CAS  Google Scholar 

  26. San Miguel JF: Supportive therapy for multiple myeloma. Trends Oncol Hematol 1996, 4:32–33.

    Google Scholar 

  27. Torra R, Blade J, Cases A, et al.: Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995, 91:854–859.

    PubMed  CAS  Google Scholar 

  28. Blade J, Fernandez-Llama P, Bosch F, et al.: Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998, 158:1889–1893.

    Article  PubMed  CAS  Google Scholar 

  29. San Miguel JF, Lahuerta JJ, García-Sanz R, et al.: Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 2000, 1:28–36.

    Article  Google Scholar 

  30. Tricot G, Alberts DS, Johnson CH, et al.: Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996, 2:947–952.

    PubMed  CAS  Google Scholar 

  31. Gucalp R, Theriault R, Gill I, et al.: Treatment of cancerassociated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Intern Med 1994, 154:1935–1944.

    Article  PubMed  CAS  Google Scholar 

  32. Purohit OP, Radstone CR, Anthony A, et al.: A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcemia of malignancy. Br J Cancer 1995, 72:1289–1293.

    PubMed  CAS  Google Scholar 

  33. Major P, Lortholary A, Hon J, et al.: Zoledronic acid is better than pamidronate in the treatment of hypercalcemia of malignancy: a grouped analysis [abstract]. Paper presented at the 36th Annual Meeting of American Society of Clinical Oncology. New Orleans, LA, May 20–23, 2000.

  34. British Columbia Cancer Agency Drug Index for Professionals: Pamidronate. http://www.bccancer.bc.ca/HPI/ DrugDatabase/DrugIndexALPro/Pamidronate.htm. Accessed February 11, 2003.

  35. Nussbaum SR, Warrell RP Jr, Rude R, et al.: Doseresponse study of alendronate sodium for the treatment of cancer-associated hypercalcemia. J Clin Oncol 1993, 11:1618–1623.

    PubMed  CAS  Google Scholar 

  36. Pecherstorfer M, Herrmann Z, Body JJ, et al.: Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996, 14:268–276.

    PubMed  CAS  Google Scholar 

  37. Cancer Pain Relief. Geneva: World Health Organization; 1996.

  38. Healey JH, Brown HK: Complications of bone metastases: surgical management. Cancer 2000, 88(Suppl 2):2940–2951.

    Article  PubMed  CAS  Google Scholar 

  39. Levine SA, Perin LA, Hayes D, Hayes WS: An evidencebased evaluation of percutaneous vertebroplasty. Manag Care 2000, 9:56–60, 63.

    PubMed  CAS  Google Scholar 

  40. Dudeney S, Lieberman IH, Reinhardt MK, Hussein M: Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol 2002, 20:2382–2387. This is a new surgical procedure for treatment of vertebral compressive fractures in patients with MM.

    Article  PubMed  CAS  Google Scholar 

  41. Belch AR, Bergsagel DE, Wilson K, et al.: Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991, 9:1397–1402.

    PubMed  CAS  Google Scholar 

  42. Daragon A, Humez C, Michot C, et al.: Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Groupe d’Etudes et de Recherches sur le Myelome (GERM). Eur J Med 1993, 2:449–452.

    PubMed  CAS  Google Scholar 

  43. Lahtinen R, Laakso M, Palva Y, et al.: Randomized, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992, 340:1049–1052.

    Article  PubMed  CAS  Google Scholar 

  44. McCloskey EV, MacLennan IC, Drayson MT, et al.: A randomised trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 1998, 100:317–325. Large randomized study demonstrating that clodronate is useful in the prevention of bone complications in patients with MM.

    Article  PubMed  CAS  Google Scholar 

  45. Heim ME, Clemens MR, Queisser W, Fessele K: Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment: a multicenter study. Onkologie 1995, 18:439–448.

    Article  Google Scholar 

  46. Berenson JR, Lichtenstein A, Porter L, et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996, 334:488–493. Randomized study demonstrating that pamidronate reduces and delays bone complications in patients with MM.

    Article  PubMed  CAS  Google Scholar 

  47. Berenson JR, Rosen LS, Howell A, et al.: Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001, 91:1191–1200.

    Article  PubMed  CAS  Google Scholar 

  48. Rosen LS, Gordon D, Kaminski M, et al.: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, doubleblind, comparative trial. Cancer J 2001, 7:377–387. Randomized study demonstrating that the use of zoledronic acid is as effective as pamidronate for the treatment of bone disease in patients with MM.

    PubMed  CAS  Google Scholar 

  49. Berenson JR, Hillner BE, Kyle RA, et al.: American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002, 20:3719–3736. Panel of experts’ recommendations for the use of bisphosphonates in patients with MM.

    Article  PubMed  Google Scholar 

  50. Martín A, García-Sanz R, Hernandez J, et al.: Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. Br J Haematol 2002, 118:239–242.

    Article  PubMed  Google Scholar 

  51. British Columbia Cancer Agency Drug Index for Professionals: Clodronate. http://www.bccancer.bc.ca/HPI/ DrugDatabase/DrugIndexALPro/Clodronate.htm. Accessed February 11, 2003.

  52. The Zometa International site. http://www.zometa.com/ index.html. Accessed February 11, 2003.

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, University Hospital of Salamanca, Paso de San Vicente 52-182, 37007, Salamanca, Spain

    Jesús F. San Miguel MD, PhD

Authors
  1. Jesús F. San Miguel MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ramón García-Sanz MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miguel, J.F.S., García-Sanz, R. Myeloma: Update on supportive care strategies. Curr. Treat. Options in Oncol. 4, 247–258 (2003). https://doi.org/10.1007/s11864-003-0026-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-003-0026-7

Keywords

Search

Navigation